| Imlygic (talimogene laherparepvec) / Amgen |
2019-004403-12: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study Essai clinique de phase II multicentrique évaluant le talimogene laherparepvec dans la maladie de Kaposi classique ou endémique |
|
|
| Not yet recruiting | 2 | 20 | Europe | talimogene laherparepvec, Solution for injection, Imlygic | ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS, Amgen | The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS traitement par T-Vec de patients atteints du Sarcome de Kaposi., Diseases [C] - Cancer [C04] | | | | |
NCT03069378: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
|
|
| Active, not recruiting | 2 | 41 | US | Talimogene Laherparepvec (T-VEC), Pembrolizumab | Memorial Sloan Kettering Cancer Center, Amgen, Merck Sharp & Dohme LLC | Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma | 03/25 | 03/25 | | |
NCT02453191: TVEC and Preop Radiation for Sarcoma (4 ml Dose) |
|
|
| Completed | 1/2 | 30 | US | Talimogene Laherparepvec, Radiotherapy | University of Iowa, Amgen | Soft Tissue Sarcoma | 01/19 | 03/23 | | |
NCT04599062: TVEC and Preop Radiation for Sarcoma (8 ml Dose) |
|
|
| Active, not recruiting | 1/2 | 8 | US | Talimogene Laherparepvec, Radiotherapy | Mohammed Milhem, Amgen | Soft Tissue Sarcoma | 02/23 | 11/24 | | |
